Expression of G-protein signaling modulator 2 in pancreatic cancer tissues
PENG Yun 1, CUI Lei 1, SHI Jian-qiang 2, CHEN Ji-xiang 1, QU Jian-guo 1, DANG Sheng-chun 1, ZHANG Jian-xin 1
(1. Department of General Surgery, Affiliated Hospital of Jiangsu University, Zhenjiang Jiangsu 212001; 2. Department of General Surgery, the No.86 Hospital of PLA, Maanshan Anhui 243000， China）
Abstract：Objective: To investigate G-protein signaling modulator 2(GPSM2) expression in human pancreatic cancer tissues and to investigate its clinical role and significance. Methods: We made the tissue microarray containing 54 pancreatic cancer samples，as well as the paired normal pancreatic tissues. The relationship between the expression of GPSM2 and the clinicopathological parameters and prognosis of the patients were analyzed by immunohistochemistry. Selected 10 cases of fresh samples of pancreatic cancer，real time PCR were used to detect GPSM2 mRNA in pancreatic cancer and adjacent pancreatic tissues，Western blotting were used to detect the expression of GPSM2 protein in pancreatic cancer and adjacent pancreatic tissue. Results: The expression of GPSM2 mRNA and protein in pancreatic cancer tissue was higher than that in normal tissues (P<0.05). Tissue microarray results showed that GPSM2 expression was significantly up-regulated in pancreatic cancer tissues(P<0.05), and its high expression ratio was 74.1%(40 cases). High GPSM2 expression was associated with larger tumor size(χ2=12.654,P＜0.01), TNM stage(χ2=16.610,P＜0.01)and as well as poor tumor differentiation(χ2=10.355,P＜0.01). Survival analysis showed that the median survival time was significantly lower in patients with high expression of GPSM2 than those with low expression (P<0.05). Conclusion: The overexpression of GPSM2 in pancreatic cancer tissues was closely related to T stage,TNM stage and poor tumor differentiation, which is related to the prognosis of the patients with pancreatic cancer.
2016, Vol. 26 
